Shanghai Securities News China Securities Network News (reporter Luo Min) Zhifei Biological announcement, the company recently learned that the lyophilized recombinant tuberculosis vaccine (AEC/BC02) developed by the company's wholly-owned subsidiary Anhui Zhifei Longkema Biopharmaceutical Co., Ltd. has completed the phase I clinical research work, and the results initially show that the vaccine has good safety and tolerability. At present, the product has completed the preparation of Phase II.A clinical trials, started subject screening, and officially launched Phase II.A clinical trials. The lyophilized recombinant TB vaccine (AEC/BC02) is intended to be used to prevent tuberculosis in people aged 18 years and older with latent tuberculosis bacteria, and belongs to the category 1 of preventive biological products.
![Chi fei long koma: The recombinant COVID-19 vaccine remains effective against the Opmi kerong variant[fig]](data:image/gif;base64,R0lGODlhAQABAIAAAP///wAAACwAAAAAAQABAAACAkQBADs=)